Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsGunnarsdottir, Anna Ingibjorg
Jonsdottir, Karen Drofn
Bjornsson, Einar Stefan
MetadataShow full item record
CitationAntibiotic susceptibility of Helicobacter pylori in Iceland. 2017, 49 (9):647-654 Infect Dis (Lond)
AbstractIncreasing resistance of Helicobacter pylori (H. pylori) to antibiotics calls for constant re-evaluation of multidrug regimens that have been used to eradicate the infection. The aim of this study was to evaluate the current antibiotic susceptibility of H. pylori in an Icelandic cohort.
Patients referred for gastroscopy were recruited prospectively. Those found to have a positive rapid urease test were included in the study. Susceptibility testing was conducted by the Epsilometer test (E-test) method for ampicillin, clarithromycin, levofloxacin, metronidazole and tetracycline. Results were obtained after three days of incubation in microaerophilic conditions at 37 °C, except for the metronidazole were the first 24 hours were anaerobic.
Of the 613 patients who underwent gastroscopy, 138 (23%) had a positive rapid urease test. H. pylori was successfully cultured from 105 (76%) of the urease test positive patients and the isolates were tested for antibiotic susceptibility. Five patients had prior H. pylori eradication. Antibiotic resistance for ampicillin, clarithromycin, levofloxacin, metronidazole and tetracycline was 0%, 9%, 4%, 1% and 0%, respectively. If those who had previously undergone eradication treatment were excluded, the resistance was 0%, 6%, 3%, 1% and 0%, respectively. Clarithromycin resistance was higher amongst women than men, 13% vs. 5%, however, not significantly. Clarithromycin resistance was 60% amongst those who had previously received eradication treatment compared to 6% of those who had not (p < .0001).
Clarithromycin resistance amongst the H. pylori isolates can be considered relatively low. Therefore, in the current cohort, standard triple-drug clarithromycin-containing regimen should remain the first-line treatment against H. pylori.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
RightsArchived with thanks to Infectious diseases (London, England)
- Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan.
- Authors: Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ
- Issue date: 2009 Jul
- Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.
- Authors: Dekhnich N, Ivanchik N, Kozlov R, Alimov A, Steshits A, Kirsov P, Pandav K
- Issue date: 2018 Dec
- Helicobacter pylori: Multiple resistance in patients from Bogotá, Colombia
- Authors: Arévalo A, Otero WA, Trespalacios AA
- Issue date: 2019 May 1
- Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes.
- Authors: Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS
- Issue date: 2017 Sep
- Antimicrobial susceptibility testing before first-line treatment for <i>Helicobacter pylori</i> infection in patients with dual or triple antibiotic resistance.
- Authors: Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L
- Issue date: 2017 May 14